MIAMI – HOPE Therapeutics, Inc. (‘HOPE’), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (‘NRx’, and collectively with HOPE, the ‘Company’) (Nasdaq: NRXP), today announced the signing and of a Stock Purchase Agreement (‘SPA’) with Smith & Sauer, LLC, as the first step in a $27.0 million financing to fund the planned acquisition of HOPE clinics. The…